For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life.

MONDAY, June 9, 2025 (HealthDay News) -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful ...

Background: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pts with pA/rEC, dostarlimab + carboplatin-paclitaxel (DOST+CP) significantly improved progression-free survival and overall survival ...

A UCLA-led study found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial ...

These findings are very important for patients with early-stage dMMR tumors because it’s likely they do not need surgery or radiation if they are treated first with immunotherapy for a sufficient ...

Background: HB0025, developed by Huaota, is a novel anti-PD-L1/VEGF bispecific antibody, with VEGFR1D2 linked at the N-terminal of anti- PD-L1 antibody. Carboplatin and paclitaxel (CP) alone or in ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

The results come from Part 1 of the study, comparing Jemperli (dostarlimab) with carboplatin-paclitaxel chemotherapy to placebo and chemo as a frontline treatment for advanced endometrial cancer ...

Identifying good mid cap stocks from hundreds of options is no easy feat. Luckily, we've done the hard work for you.